Sucampo Wins Approval for Expanded Use of Amitiza in U.S.

Sucampo Pharmaceuticals Inc. won approval to expand the use of its Amitiza drug to treat opioid-induced constipation in patients with chronic non-cancer pain. The approval spurred the company’s shares to the greatest one-day gain in more than four years.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.